Latest News on PRME

Financial News Based On Company


Advertisement
Advertisement

Prime Medicine (NASDAQ:PRME) Stock Rating Reaffirmed as Buy by HC Wainwright

https://www.marketbeat.com/instant-alerts/analyst-prime-medicine-nasdaq-prme-stock-rating-reaffirmed-as-buy-by-hc-wainwright-2026-11-16/
HC Wainwright reaffirmed its "Buy" rating on Prime Medicine (NASDAQ:PRME) and maintained an $8 price target, suggesting an 87.35% upside. The company reported quarterly EPS of -$0.22, exceeding estimates, and revenue of $4.21 million. Overall analyst sentiment is "Moderate Buy" with an average price target of $7.86.

Prime Medicine closes $143.7M public offering at $3.50 per share

https://www.streetinsider.com/Equity+Offerings/Prime+Medicine+closes+%24143.7M+public+offering+at+%243.50+per+share/27336532.html
Prime Medicine, Inc. (Nasdaq: PRME) has successfully closed an underwritten public offering, raising approximately $143.7 million. The offering included 41,071,428 shares of common stock sold at $3.50 per share, with joint book-running managers including Jefferies, TD Cowen, and Goldman Sachs & Co. LLC.

Prime Medicine Q3 Results: EPS beats estimate, sales up 244% YoY

https://scanx.trade/stock-market-news/companies/prime-medicine-q3-results-eps-beats-estimate-sales-up-244-yoy/56065074
Prime Medicine Inc. reported strong third-quarter results, with EPS of $(0.22) beating the consensus estimate by 12% and sales reaching $4.213 million, a 243.92% increase year-over-year. Despite the significant revenue growth, the loss per share narrowed by only about one-third, suggesting elevated operating costs relative to the incremental revenue. The stock performance for Prime Medicine shows a 19.86% increase over the last year.

Prime Medicine closes $143.7M public offering at $3.50/share

https://www.investing.com/news/company-news/prime-medicine-closes-1437m-public-offering-at-350share-93CH-5023334
Prime Medicine Inc. (NASDAQ:PRME) successfully completed a public offering, selling 41,071,428 shares of common stock at $3.50 per share, which included the full exercise of the underwriters' option for additional shares. The offering generated gross proceeds of approximately $143.7 million for the biotechnology company specializing in gene editing therapies. Jefferies, TD Cowen, and Goldman Sachs & Co. LLC acted as joint book-running managers for the transaction.

Prime Medicine Announces Closing of Public Offering and

https://www.globenewswire.com/news-release/2026/11/12/3402256/0/en/prime-medicine-announces-closing-of-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares.html
Prime Medicine, Inc. announced the closing of its underwritten public offering, which included the full exercise of the underwriters’ option to purchase additional shares. The offering involved 41,071,428 shares of common stock at $3.50 per share, generating approximately $143.7 million in gross proceeds. Jefferies, TD Cowen, and Goldman Sachs & Co. LLC acted as joint book-running managers.
Advertisement

Prime Medicine, Inc. (PRME) Tops Q3 EPS by 14c

https://www.streetinsider.com/Earnings/Prime+Medicine%2C+Inc.+%28PRME%29+Tops+Q3+EPS+by+14c/27337820.html
Prime Medicine, Inc. (PRME) announced its third-quarter earnings, reporting an EPS of ($0.22), which was $0.14 better than the analyst estimate of ($0.36). The company's revenue for the quarter reached $4.21 million.

Prime Medicine Closes $143.7 Million Public Offering of Common Stock

https://www.quiverquant.com/news/Prime+Medicine+Closes+%24143.7+Million+Public+Offering+of+Common+Stock
Prime Medicine, Inc. successfully closed a public offering of 41,071,428 shares of common stock at $3.50 per share, raising approximately $143.7 million in gross proceeds. The offering included the full exercise of the underwriters' option for additional shares and was managed by Jefferies, TD Cowen, and Goldman Sachs & Co. LLC. This capital injection will support the company's efforts to develop one-time curative genetic therapies using its proprietary Prime Editing platform, with a focus on liver, lung, and oncology programs.

A Wilson disease gene-editing trial has dosed its first patient. Initial data are expected in 2027.

https://www.stocktitan.net/news/PRME/prime-medicine-reports-third-quarter-2026-financial-results-and-tqoo9d5a0zsz.html
Prime Medicine reported a narrower net loss of $39.043 million in Q3 2026 and advanced its gene-editing clinical programs. The company dosed the first patient in its PM577a trial for Wilson disease and received FDA clearance for PM647 in Alpha-1 Antitrypsin Deficiency, with initial data from both expected in 2027. Additionally, Prime Medicine completed a public offering that raised $143.7 million gross, providing a pro-forma cash position of approximately $209.5 million, expected to fund operations through 2027.

Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates

https://www.globenewswire.com/news-release/2026/11/12/3402154/0/en/prime-medicine-reports-third-quarter-2026-financial-results-and-provides-business-updates.html
Prime Medicine (Nasdaq: PRME) reported its Q3 2026 financial results, highlighting significant progress in its clinical programs. The company dosed the first patient in its Phase 1/2 clinical trial for PM577a in Wilson disease, received FDA clearance for PM647 in Alpha-1 Antitrypsin Deficiency, and plans a BLA submission for PM359 in early 2027. Prime Medicine also completed a public offering, raising $143.7 million in gross proceeds, extending its cash runway through 2027.

Tracking Cathie Wood: Adds Prime Medicine and Archer Aviation, Trims Absci and BYD

https://www.moomoo.com/community/feed/tracking-cathie-wood-adds-prime-medicine-and-archer-aviation-trims-117602204844038
Cathie Wood's ARK Invest made strategic rebalancing moves, adding to positions in Prime Medicine (PRME.US) and Archer Aviation (ACHR.US), reflecting conviction in gene editing and urban air mobility. Concurrently, ARK trimmed holdings in Absci Corp (ABSI.US) and BYD Company ADR (BYDDY.US), reallocating capital from competitive sectors to focus on earlier-stage disruptive technologies. These adjustments aim to deepen ARK's long-term moat in disruptive innovation.
Advertisement

Form 424B5 Prime Medicine Inc For: 11 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-424b5-prime-medicine-inc-for-11-november-93CH-4949158
This article announces the filing of Form 424B5 by Prime Medicine Inc. on November 11. It's a brief update from Investing.com, likely indicating a regulatory filing related to the company's financial activities or offerings. The content is primarily a placeholder for the filing information itself.

Prime Medicine prices $125M public offering at $3.50 per share

https://www.tradingview.com/news/seekingalpha:d9eb1cf7d094b:0-prime-medicine-prices-125m-public-offering-at-3-50-per-share/
Prime Medicine announced it priced an underwritten public offering of 35.7 million shares of common stock at $3.50 per share, aiming to raise approximately $125 million. The company, which is developing gene-editing therapies, also granted underwriters a 30-day option to purchase an additional 5.36 million shares. The offering is expected to close around November 12, and Prime Medicine's stock price experienced a nearly 4% drop after market hours on Tuesday.

Prime Medicine Announces Pricing of $125 Million Public Offering of Common Stock

https://www.quiverquant.com/news/Prime+Medicine+Announces+Pricing+of+%24125+Million+Public+Offering+of+Common+Stock
Prime Medicine, Inc. has announced the pricing of a public offering of 35,714,286 shares of its common stock at $3.50 per share, aiming to raise approximately $125 million before deductions. The company has granted underwriters a 30-day option to purchase an additional 5,357,142 shares. The offering is expected to close around November 12, 2026, and the proceeds will be used to fund ongoing and future genetic therapy projects.

Prime Medicine prices public offering at $3.50 per share

https://www.streetinsider.com/Equity+Offerings/Prime+Medicine+prices+public+offering+at+%243.50+per+share/27325446.html
Prime Medicine, Inc. (Nasdaq: PRME) has priced an underwritten public offering of 35,714,286 shares of common stock at $3.50 per share, aiming to generate approximately $125.0 million in gross proceeds. The company has also granted underwriters an option to purchase an additional 5,357,142 shares. The offering is expected to close around November 12, 2026, with Jefferies, TD Cowen, and Goldman Sachs & Co. LLC serving as joint book-running managers.

Prime Medicine Announces Pricing of Public Offering of Common Stock

https://www.manilatimes.net/2026/11/11/tmt-newswire/globenewswire/prime-medicine-announces-pricing-of-public-offering-of-common-stock/2467186
Prime Medicine, Inc. announced the pricing of an underwritten public offering of 35,714,286 shares of its common stock at $3.50 per share, aiming to raise approximately $125.0 million. The biotechnology company also granted underwriters a 30-day option to purchase an additional 5,357,142 shares. The offering is expected to close around November 12, 2026, with Jefferies, TD Cowen, and Goldman Sachs & Co. LLC acting as joint book-running managers.
Advertisement

Prime Medicine prices $125M stock offering at $3.50/share

https://www.investing.com/news/company-news/prime-medicine-prices-125m-stock-offering-at-350share-93CH-5017543
Prime Medicine Inc. (NASDAQ:PRME) has announced an underwritten public offering of 35,714,286 shares of common stock at $3.50 per share, aiming to raise approximately $125 million. The biotechnology company has also granted underwriters an option to purchase additional shares. The offering is expected to close around November 12, 2026, with Jefferies, TD Cowen, and Goldman Sachs & Co. LLC serving as joint book-running managers.

About $13.7M is restricted as Prime Medicine (PRME) estimates its quarter-end cash and investments.

https://www.stocktitan.net/sec-filings/PRME/8-k-prime-medicine-inc-reports-material-event-d735c68c1002.html
Prime Medicine, Inc. (PRME) reported preliminary, unaudited estimates of approximately $61.2 million in cash, cash equivalents, and short-term investments as of September 30, 2026, with an additional $13.7 million in restricted cash. The company also provided updates on its clinical programs, including anticipated initial data for PM577a and PM647 in 2027, and a planned Biologics License Application (BLA) submission for PM359 in chronic granulomatous disease in the first half of 2027. This financial update and clinical pipeline progress were disclosed in an 8-K filing.

Prime Medicine plans $125M common stock offering

https://www.quantisnow.com/insight/sec-form-424b5-filed-by-prime-medicine-inc-6784483
Prime Medicine (NASDAQ: PRME) has filed a preliminary prospectus supplement to offer $125 million in common stock, with an additional $18.75 million option for underwriters. The offering will dilute existing shareholders, and future equity sales could occur at lower prices. The company also plans to submit a Biologics License Application for PM359 in the first half of 2027, following its RMAT designation from the FDA.

Prime Medicine to Present at Jefferies Global Healthcare Conference

https://www.globenewswire.com/news-release/2026/11/09/3398380/0/en/prime-medicine-to-present-at-jefferies-global-healthcare-conference.html
Prime Medicine, Inc. announced that CEO Allan Reine, M.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 16, 2026. The company, a biotechnology firm focused on gene editing therapies, will make a live audio webcast of the presentation available on its website. Prime Medicine is advancing a diversified portfolio of investigational therapeutic programs in liver, lung, immunology, and oncology.

Jones Trading initiates Prime Medicine stock coverage with buy rating By Investing.com

https://uk.investing.com/news/stock-market-news/jones-trading-initiates-prime-medicine-stock-coverage-with-buy-rating-93CH-4960384
Jones Trading has initiated coverage on Prime Medicine Inc. (NASDAQ:PRME) with a Buy rating and a $6.00 price target, citing the company's advancing gene editing pipeline. The valuation is based on sales projections for PM577 in Wilson’s Disease and PME647 for alpha-1 antitrypsin deficiency, each with a 20% probability of success. Other firms like Citizens and BMO Capital have also recently issued positive ratings, highlighting Prime Medicine's innovative gene-editing platform.
Advertisement

Jones Trading Assumes Prime Medicine (PRME) at Buy

https://www.streetinsider.com/Analyst+Comments/Jones+Trading+Assumes+Prime+Medicine+%28PRME%29+at+Buy/27294068.html
Jones Trading analyst Catherine Novack has initiated coverage on Prime Medicine (NASDAQ: PRME) with a Buy rating and a $6.00 price target, an increase from a previous target of $5. The valuation is based on potential sales from PM577 for Wilson's Disease and PME647 for alpha-1 antitrypsin deficiency (AATD), with initial data for AATD expected in 2027. The analyst also notes potential for accelerated approvals for other mutations based on non-clinical data following recent FDA draft guidance.

Prime Medicine (PRME) Stock Price, Chart & Analysis

https://www.debelegger.nl/en/stock/PRME.US
This article provides a detailed analysis of Prime Medicine (PRME) stock, including its current price, market capitalization, quality score, and financial figures. It highlights the company's lack of profitability, absence of dividends, and moderate revenue growth, offering a comprehensive overview for potential investors. The analysis also includes a Belegger score based on Buffett and Lynch metrics and various future price scenarios.

Wall Street Zen Upgrades Prime Medicine (NASDAQ:PRME) to "Hold"

https://www.marketbeat.com/instant-alerts/analyst-wall-street-zen-upgrades-prime-medicine-nasdaq-prme-to-hold-2026-10-31/
Wall Street Zen has upgraded Prime Medicine (NASDAQ:PRME) from a "sell" to a "hold" rating, though the overall analyst consensus remains a "Moderate Buy" with an average price target of $7.47. Despite opening at $4.72, above its 50-day and 200-day moving averages, the biotechnology company missed revenue expectations while meeting EPS estimates. Institutional investors currently hold about 70.37% of the stock.

Prime Medicine doses first patient in Wilson disease editing trial

https://www.findarticles.com/prime-medicine-first-patient-wilson-disease-prime-editing-trial/
Prime Medicine has dosed the first patient in a Phase 1/2 clinical trial for PM577a, an experimental gene-editing treatment for Wilson disease targeting the H1069Q DNA variant in liver cells. This marks a significant operational milestone for prime editing, moving the therapy into human testing, though no safety or efficacy data is yet available. The trial aims to assess safety and biological activity by measuring copper-related biomarkers, with initial data expected in 2027.

Anthropic acquires a one-person biotech that used Claude to coordinate 11 labs

https://www.rdworldonline.com/anthropic-acquires-mithril-medicine-one-person-biotech/
Anthropic has acquired Mithril Medicine, a one-person biotech company founded by Cody Tranbarger, which utilized Anthropic's AI, Claude, to manage experiments and logistics across 11 external laboratories. Mithril Medicine's programs target two rare muscular dystrophies and have become Anthropic's first internal drug-development efforts. The company achieved mouse proof of principle for LAMA2-related congenital muscular dystrophy in under 18 months, with plans to select formal drug candidates in 2027 and potentially begin human trials as early as late 2028.
Advertisement

Prime Medicine, Inc. Estimates – NASDAQ:PRME

https://www.tradingview.com/symbols/NASDAQ-PRME/financials-estimates/
This article provides an overview of Prime Medicine, Inc. (NASDAQ: PRME) financial estimates available on TradingView. It details how users can explore reported financial data and analyst estimates for the company across various financial statements and valuation metrics. The platform allows comparison of actual results with average, high, and low estimates, and visualization of trends over time.

Prime Medicine launches first in-body prime editing trial for Wilson disease

https://www.dongascience.com/en/news/80515
Prime Medicine has initiated the first in-body clinical trial using prime editing technology to treat Wilson disease, a rare inherited disorder. This advanced gene-editing method aims to correct the genetic mutations in liver cells responsible for copper accumulation, offering a potential one-time, lifelong therapy. Unlike previous ex-vivo applications, this trial involves direct in-body editing, presenting both opportunities for broader application and challenges in precise delivery and outcome verification.

Prime Medicine Inc. (PRME) Stock Price | Live Quotes & Charts | NASDAQ

https://stockstotrade.com/quote/PRME/
This NASDAQ page provides live quotes and charts for Prime Medicine Inc. (PRME) stock, showing its current price of $3.47, up 3.75%. The page also notes that there is no analyst rating or earnings information currently available for the company. It encourages users to get real-time quotes and offers a stock trading bootcamp.

Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why

https://es.tradingview.com/news/zacks:56f159971094b:0-prime-medicine-stock-rallies-nearly-26-in-a-month-here-s-why/
Prime Medicine's stock has surged by nearly 26% over the past month due to encouraging clinical and regulatory advancements in its gene-editing pipeline. The company received FDA clearance for its investigational therapy PM647 for alpha-1 antitrypsin deficiency (AATD) and has begun dosing the first patient in a phase I/II study for PM577a for Wilson disease. These milestones underscore the potential of Prime Medicine's Prime Editing platform to address the underlying genetic causes of these diseases, with initial data for PM577a expected in 2027.

Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why

https://www.tradingview.com/news/zacks:56f159971094b:0-prime-medicine-stock-rallies-nearly-26-in-a-month-here-s-why/
Prime Medicine's stock has rallied nearly 26% over the past month, driven by positive clinical and regulatory advancements in its gene-editing pipeline. The company received FDA clearance for its investigational therapy PM647 for alpha-1 antitrypsin deficiency (AATD) and dosed the first patient in a Phase I/II study for PM577a targeting Wilson disease. These developments highlight the potential of Prime Medicine's Prime Editing platform to address the underlying causes of genetic diseases.
Advertisement

Prime Medicine (NASDAQ:PRME) Stock Falls 7.6% - Here's Why

https://www.marketbeat.com/instant-alerts/price-prime-medicine-nasdaq-prme-stock-falls-76-heres-why-2026-10-08/
Prime Medicine (NASDAQ:PRME) stock fell 7.6% during mid-day trading on Thursday, closing at $3.6050 with reduced trading volume. The decline follows mixed analyst ratings, with a consensus of "Moderate Buy" but recent downgrades. The company's last quarterly earnings reported an EPS in line with estimates but revenue significantly below forecasts, leading analysts to anticipate a full-year loss.

Companies Like Prime Medicine (NASDAQ:PRME) Could Be Quite Risky

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prme/prime-medicine/news/companies-like-prime-medicine-nasdaqprme-could-be-quite-risk
Prime Medicine (NASDAQ:PRME) faces significant financial risk due to its high cash burn rate and limited cash runway. The company burnt through US$157m in the last year, leaving it with only about 7 months of cash, while also increasing its cash burn by 47% and seeing operating revenue decline by 18%. This situation suggests a strong need for the company to either drastically reduce its expenditures or raise additional capital, potentially leading to costly shareholder dilution.

Prime Medicine doses first patient in Wilson disease gene therapy trial

https://www.investing.com/news/company-news/prime-medicine-doses-first-patient-in-wilson-disease-gene-therapy-trial-93CH-4931986
Prime Medicine Inc. announced the dosing of the first patient in its Phase 1/2 clinical trial for PM577a, an investigational gene therapy for Wilson disease. This therapy targets the H1069Q mutation, the most common cause of the disease in North America and Europe, and marks the company's first in vivo Prime Editing therapy to enter clinical study. The trial aims to evaluate the safety, tolerability, and preliminary efficacy of PM577a as a potential one-time treatment for this genetic disorder.

Prime Medicine doses first patient in prime-editing trial for H1069Q Wilson disease

https://allsci.com/news/clinical-trials/wilson-disease-prime-medicine-doses-first-patient/
Prime Medicine has dosed the first patient in a Phase I/II trial for PM577a, an investigational prime-editing therapy targeting Wilson disease caused by the H1069Q mutation. The study will evaluate ascending doses in adults and adolescents, with initial clinical data expected in 2027. PM577a aims to correct the genetic defect responsible for the disease, offering a potential one-time intravenous treatment.

Prime Medicine (PRME) Stock Draws Traders On FDA Trial Wins

https://timothysykes.com/news/prime-medicine-inc-prme-news-2026_10_06/
Prime Medicine (PRME) stock rose by 8.88% due to positive developments in its gene-editing therapy pipeline, specifically the FDA clearance for PM647 and the first-in-human dosing of PM577a. These milestones, despite the company's pre-revenue status and high burn rate, have attracted traders looking for catalyst-driven opportunities. Oppenheimer reaffirmed an Outperform rating with an $11 price target, highlighting the validation of Prime Medicine's modular gene-editing platform.
Advertisement

PRME Stock Climbs As FDA Greenlights Gene-Editing Trials

https://stockstotrade.com/news/prime-medicine-inc-prme-news-2026_10_06/
Prime Medicine Inc. (PRME) stock has surged by 8.88% due to heightened investor optimism after the FDA cleared its Investigational New Drug (IND) application for PM647, a gene-editing therapy for Alpha‑1 Antitrypsin Deficiency, enabling U.S. trials. The company also announced the first patient dosed in a global Phase 1/2 trial for PM577a for Wilson disease and received FDA Rare Pediatric Disease designation for it. Oppenheimer reaffirmed an Outperform rating and an $11 target for PRME, noting the clinical progress while also flagging financing pressures.

Prime Medicine doses first patient in Wilson disease gene therapy trial

https://ng.investing.com/news/stock-market-news/prime-medicine-doses-first-patient-in-wilson-disease-gene-therapy-trial-93CH-2721640
Prime Medicine Inc. (NASDAQ:PRME) has dosed the first patient in its Phase 1/2 clinical trial for PM577a, an investigational gene therapy for Wilson disease caused by the H1069Q mutation. This trial marks the company's first clinical study of an in vivo Prime Editing therapy and has received Rare Pediatric Disease designation from the FDA. Initial clinical data from the trial, which will evaluate safety, tolerability, and preliminary efficacy in adults and adolescents, is expected in 2027.

Prime Medicine doses first patient in Wilson disease gene therapy trial

https://ca.investing.com/news/stock-market-news/prime-medicine-doses-first-patient-in-wilson-disease-gene-therapy-trial-93CH-4865788
Prime Medicine Inc. (NASDAQ:PRME) has dosed its first patient in a Phase 1/2 clinical trial for PM577a, an investigational gene therapy designed to treat Wilson disease caused by the H1069Q mutation. This marks the company's first in vivo Prime Editing therapy in clinical study and its first liver-focused program. The U.S. FDA has granted Rare Pediatric Disease designation to PM577a, and initial clinical data is expected in 2027.

Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease

https://www.globenewswire.com/news-release/2026/10/05/3374466/0/en/prime-medicine-announces-first-patient-dosed-in-global-phase-1-2-clinical-trial-of-pm577a-for-h1069q-mutated-wilson-disease.html
Prime Medicine announced the first patient has been dosed in its global Phase 1/2 clinical trial for PM577a, an investigational in vivo Prime Editor targeting H1069Q-mutated Wilson disease. This marks the initiation of the company's first clinical study using its Prime Editing therapy and its liver franchise, with initial data expected in 2027. The U.S. FDA also granted Rare Pediatric Disease designation to PM577 for Wilson disease, highlighting the significant unmet need for curative therapies for this serious genetic disorder.

Prime Medicine Doses First Patient in Global Phase 1/2 Trial of PM577a for Wilson Disease and Receives FDA Rare Pediatric Disease Designation

https://www.quiverquant.com/news/Prime+Medicine+Doses+First+Patient+in+Global+Phase+1%2F2+Trial+of+PM577a+for+Wilson+Disease+and+Receives+FDA+Rare+Pediatric+Disease+Designation
Prime Medicine has initiated a global Phase 1/2 clinical trial for PM577a, an investigational one-time therapy for Wilson disease targeting the H1069Q mutation, with the first patient now dosed. The therapy has also received Rare Pediatric Disease designation from the FDA, highlighting the significant unmet medical need for effective treatments. Initial clinical data for PM577a is anticipated in 2027, offering potential for a curative solution for this genetic disorder.
Advertisement

Prime Medicine, Inc. (PRME) options chain – Yahoo Finance

https://sg.finance.yahoo.com/quote/PRME/options/?date=1863475200&straddle=false&type=all
This article provides the options chain for Prime Medicine, Inc. (PRME), displaying call and put options with an expiration date of January 19, 2029. It includes various strike prices, last trade dates, last prices, bid/ask spreads, volume, open interest, and implied volatility for each option contract. The current stock price for PRME is also noted.

Prime Medicine (NASDAQ:PRME) Cut to "Sell" at Wall Street Zen

https://www.marketbeat.com/instant-alerts/analyst-prime-medicine-nasdaq-prme-cut-to-sell-at-wall-street-zen-2026-10-03/
Wall Street Zen has downgraded Prime Medicine (NASDAQ:PRME) from "Hold" to "Sell," despite a broader analyst consensus of "Moderate Buy" with a $7.47 target price. The company's shares opened at $2.98, near their 12-month low, and reported a quarterly loss of $0.24 per share on revenue of $1.15 million, significantly missing analyst estimates. Institutional investors, including Alphabet and BlackRock, hold a substantial 70.37% stake in the company.

Prime Medicine, Inc. (PRME) Gets a Buy from H.C. Wainwright

https://www.theglobeandmail.com/investing/markets/stocks/PRME/pressreleases/4930076/prime-medicine-inc-prme-gets-a-buy-from-hc-wainwright/
H.C. Wainwright analyst Arthur He CFA reiterated a Buy rating on Prime Medicine, Inc. (PRME) with an $8.00 price target, based on the company's latest earnings report. The company reported a quarterly revenue of $1.15 million and a GAAP net loss of $42.11 million for the quarter ending June 30. The general Street consensus for Prime Medicine, Inc. is a Strong Buy with a $7.67 average price target.

Prime Medicine's (PRME) Buy Rating Reaffirmed at Chardan Capital

https://www.marketbeat.com/instant-alerts/analyst-prime-medicine-nasdaq-prme-stock-keeps-buy-rating-at-chardan-capital-2026-09-25/
Chardan Capital has reaffirmed its "buy" rating on Prime Medicine (NASDAQ:PRME), setting a price target of $7.00, suggesting a potential upside of 134.11%. Other analysts have also issued positive ratings, contributing to a consensus "Moderate Buy" rating with an average target price of $7.47. The company's stock recently traded down, and it reported a quarterly EPS of ($0.24) and revenue of $1.15 million, below analyst estimates.

Bank of America Corp DE Makes New $3.62 Million Investment in Prime Medicine, Inc. $PRME

https://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-makes-new-362-million-investment-in-prime-medicine-inc-prme-2026-09-30/
Bank of America Corp DE has invested $3.62 million in Prime Medicine, Inc. (NASDAQ:PRME), acquiring 981,335 shares. This new position gives Bank of America a 0.54% stake in the biotechnology company. Institutional investors collectively own 70.37% of Prime Medicine, which focuses on developing genetic medicines using its proprietary Prime Editing platform.
Advertisement

Prime Medicine receives FDA clearance for PM647 in alpha-1 antitrypsin deficiency

https://allsci.com/news/biotech/pm647-fda-clearance-prime-medicine-receives-for/
Prime Medicine (Nasdaq: PRME) has received FDA clearance for PM647, a one-time in vivo prime editing therapy for alpha-1 antitrypsin deficiency (AATD). This therapy aims to correct the genetic defect, addressing both lung and liver manifestations with a single treatment. Initial clinical data are anticipated in 2027, placing PM647 in a competitive field of genetic medicines for AATD.

Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm647 In Alpha-1 Antitrypsin Deficiency

https://www.tradingview.com/news/reuters.com,2026:newsml_TUA3ZFFJ5:0-prime-medicine-announces-u-s-fda-clearance-of-investigational-new-drug-application-for-pm647-in-alpha-1-antitrypsin-deficiency/
Prime Medicine has announced that the U.S. FDA has cleared its Investigational New Drug (IND) application for PM647. This drug is intended for the treatment of Alpha-1 Antitrypsin Deficiency. The clearance allows Prime Medicine to proceed with clinical trials for PM647.

PRME Stock Dips As Prime Medicine Faces Steep Losses

https://stockstotrade.com/news/primemedicineinc-prme-news-2026_09_25-2/
Prime Medicine Inc. (PRME) stock has fallen by 3.91% due to cautious sentiment regarding its gene-editing therapy pipeline. The company is facing significant losses and a severe cash burn, with analyst sentiment remaining neutral. Technically, PRME is in a short-term downtrend, trading below key resistance levels, indicating persistent selling pressure despite its balance sheet cushion.

Prime Medicine Gets FDA Green Light for Gene Editing Study

https://www.benzinga.com/markets/biotech/26/09/62004493/prime-medicine-gets-fda-green-light-for-gene-editing-study
Prime Medicine (NASDAQ: PRME) has received FDA clearance for its Investigational New Drug (IND) application for PM647, a gene-editing therapy for Alpha-1 Antitrypsin Deficiency (AATD). The company plans to initiate a global Phase 1/2 clinical trial to assess the safety and efficacy of PM647, which aims to correct the E342K (Pi*Z) mutation in the SERPINA1 gene. PM647 is designed to restore functional M-AAT protein levels to address both liver and lung complications of AATD.

FDA Clears Prime Medicine to Start Gene Editing Trial After Beam Dispute

https://www.genomeweb.com/business-news/regulatory/fda/clearance/gnw-prime-medicine-gene-editing-beam-aatd-20260925/
The FDA has given Prime Medicine clearance to begin a gene editing trial. This decision follows a dispute with Beam Therapeutics. The article was published on September 25, 2026.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement